<DOC>
	<DOCNO>NCT02998242</DOCNO>
	<brief_summary>To study safety efficacy apatinib combination radiotherapy patient symptomatic bony disease prostate cancer ( SBPC ) , base potential synergistic antitumor activity Apatinib Stereotactic Body Radiation Therapy ( SBRT ) .</brief_summary>
	<brief_title>Apatinib Combination With Stereotactic Body Radiation Therapy ( SBRT ) Treatment Symptomatic Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<criteria>Histologic diagnosis adenocarcinoma prostate Metastatic symptomatic prostate cancer ( positive bone scan measurable disease ) Patients must stop use herbal product know decrease PSA level ( eg. , saw palmetto PCSPES ) systemic topical corticosteroid least 4 week prior screen . Progressive disease must document discontinuation product . Progressive disease androgen deprivation ( hormone therapy ) . For patient measurable disease , progression define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . For patient progression , without measurable disease , positive bone scan elevate PSA require . Patients receive bisphosphate therapy must stable dos least 4 week stable symptom prior enrollment . No prior chemotherapy immunotherapy ( tumor vaccine , cytokine , growth factor give control prostate cancer ) . Prior radiation therapy complete least 4 week prior enrollment . No prior radiopharmaceutical ( strontium , samarium ) within 8 week prior enrollment . History severe hypersensitivity reaction drug formulate polysorbate 80 . Patients active autoimmune disease history autoimmune disease require systemic steroid immunosuppressive medication , except patient vitiligo . Prior therapy anticytotoxic Tlymphocyte antigen 4 ( antiCTLA4 ) antibody . Active infection require therapy . Concurrent medical condition require use systemic topical corticosteroid ; systemic topical corticosteroid must discontinue least 4 week prior enrollment . The use inhale corticosteroid acceptable .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>